The safety of neoantigen vaccine and changes in health-related quality of life
itching, injection-site reaction, headache
ADVERSE REACTIONS, MINOR, ADVERSE EVENTS
Since there was a drug washout period of at least 2 weeks between vaccine treatment and conventional treatment, we could distinguish the clinical adverse reactions after vaccine treatment from those of conventional treatment. All six enrolled patients received five planned priming phase vaccinations. As for booster vaccinations, patients W01, W02, W03, and W10 received four, seven, three, and two booster vaccinations, respectively. No obvious treatment-related adverse events were observed, and routine blood/biochemical tests did not indicate any obvious abnormalities during vaccinations. After vaccination, all patients had mild injection-site reaction (Grade 1). Patient W02 experienced minor itching on his back following the third vaccination treatment, and patient W09 experienced minor headache following the first vaccination (Table Treatment-related adverse events in the patients*Including all patients who received at least one dose of trial treatmentChanges in health-related quality of life were measured on the FACT-C as listed in Table Quality of life at baseline and at 20 weeks (